The p53 inhibitor murine double-minute gene 2 (Mdm2) is a target for potential cancer therapies, however increased p53 function can be lethal. To directly address whether reduced Mdm2 function can inhibit tumorigenesis without causing detrimental side effects, we exploited a hypomorphic murine allele of mdm2 to compare the effects of decreased levels of Mdm2 and hence increased p53 activity on tumorigenesis and life span in mice. Here we report that mice with decreased levels of Mdm2 are resistant to tumor formation yet do not age prematurely, supporting the notion that Mdm2 is a promising target for cancer therapeutics.
Activation of the p53 tumor suppressor is a current goal of many cancer therapeutic strategies (Lane and Fischer 2004; Vassilev et al. 2004; Yang et al. 2005) . As a key proximal regulator of p53, murine double-minute gene 2 (Mdm2) is a potential target for such chemotherapeutics, particularly in tumors in which p53 function is limited through mechanisms other than mutational inactivation. Mdm2 is a powerful inhibitor of p53, limiting p53 function by several mechanisms. It directly binds the transcriptional activation domain of p53 and blocks interactions with the basic transcription machinery (Momand et al. 1992; Thut et al. 1997 ). In addition, it promotes nuclear export of p53 and transfers ubiquitin to p53, thereby enhancing its degradation (Honda et al. 1997; Roth et al. 1998) . As little as a twofold decrease in Mdm2 expression increases basal p53 function in mice (Mendrysa et al. 2003) , highlighting the exquisite sensitivity of p53 to Mdm2 levels. Conversely, a naturally occurring polymorphism in the human mdm2 gene (SNP309) has been identified that allows increased mdm2 expression and thereby decreased p53 function in people (Bond et al. 2004) . SNP309 is strongly associated with a 10-yr acceleration of tumor onset, presumably due to decreased p53 tumor suppressor function. Small molecule inhibitors of Mdm2 have been developed that reduce tumor growth specifically by increasing the activity of p53 (Vassilev et al. 2004) , thereby advancing the concept of Mdm2 as a chemopreventive or therapeutic target. Together, these studies suggest that modest inhibition of Mdm2 could potentially serve as an effective anticancer therapy.
The utility of this approach depends on whether therapeutic doses of Mdm2 inhibitors cause unacceptable side effects (Lane and Fischer 2004) . Mdm2 is a critical survival factor as evidenced by the embryonic death of mice lacking Mdm2 (Jones et al. 1995; Montes de Oca Luna et al. 1995) and the lymphopenia of mice expressing ∼30% of the wild-type level of Mdm2 (Mendrysa et al. 2003) . To date, these as well as all other phenotypes associated with loss or decreased levels of Mdm2 have been demonstrated to be rescued by loss of p53, indicating that increased p53 activity is a direct consequence of decreased mdm2 expression. While activation of the tumor-suppressive function of p53 may be beneficial, there is controversial evidence that constitutively high p53 activity in nontumor cells accelerates aging in mice (Garcia-Cao et al. 2002; Tyner et al. 2002; Maier et al. 2004) . If tumor-suppressive doses of p53 activity cause aging and/or lymphopenia, the utility of compounds that inhibit Mdm2 function and activate p53 may be limited.
Several studies have attempted to address the question of whether p53-mediated tumor suppression comes at the cost of accelerated aging, and they have provided conflicting results. Tyner et al. (2002) generated mice carrying a mutant p53 gene (p53 m ) that encodes a protein that can stimulate the activity of endogenous p53. In this strain, the incidence of tumorigenesis is reduced dramatically. However, p53 m/+ mice die at younger ages than do wild-type mice, and prematurely exhibit several symptoms of aging including weight loss, lordokyphosis, thin skin, and osteoporosis, prompting the interpretation that high p53 activity causes tumor suppression at the cost of accelerated aging (Donehower 2002; Febeyre and Lowe 2002) . However, despite their increased resistance to tumor formation, p53 m/+ mice have not been demonstrated to have more p53 activity than wild-type mice. Moreover, it was recently reported that the generation of p53 m/+ mice led to the deletion of 24 genes, which is hypothesized to contribute to the aging phenotypes (Gentry and Venkatachalam 2005) . Thus the etiology of the aging phenotypes in p53 m/+ mice is not clear. Additional studies have not clarified whether p53 promotes aging. "Super p53" mice carrying multiple transgenes of wild-type p53 age normally (Garcia-Cao et al. 2002) . These mice have excessive levels of p53 activity following treatment with chemical carcinogens or radia-tion. However, basal levels of p53 activity are wild type (Garcia-Cao et al. 2002) . Thus, these mice are not an appropriate system in which to test whether p53 activity accelerates aging. Indeed, the authors of this work suggested that constitutively high levels of p53 activity may be necessary to accelerate aging. More recently, Maier et al. (2004) found evidence of accelerated aging in transgenic mice carrying a truncated form of p53 that enhances some activities of endogenous wild-type p53. However, since these mice showed decreases in other p53 functions, the data could be interpreted as consistent with a role for p53 in preventing, rather than accelerating, aging. Indeed the model put forth by these authors suggests that insulin-like growth-factor signaling, which is inhibited by p53, promotes aging in these mice. Thus, it remains unclear whether increased p53 activity through Mdm2 inhibition would accelerate aging.
To directly test whether decreased Mdm2 activity and consequently high p53 activity suppresses tumor formation at the cost of accelerated aging, we took advantage of mice genetically engineered to express low levels of mdm2. Mdm2 puro/⌬7-12 mice, which have one hypomorphic and one null allele of mdm2, express ∼30% of the wild-type level of mdm2 and demonstrate an obvious increase in many functions of endogenous, wild-type p53 (Mendrysa et al. 2003) . The mice are small, lymphopenic, and radiosensitive, all due to high p53 activity. All tissues of mdm2 puro/⌬7-12 mice have elevated levels of p53-dependent transcription and a subset undergoes spontaneous, p53-mediated apoptosis. All observed phenotypes of mdm2 puro/⌬7-12 mice are completely rescued by deletion of p53 (Mendrysa et al. 2003) . As endogenous p53 is constitutively active in mdm2 puro/⌬7-12 mice, these mice are an ideal model for studying the physiological consequences of Mdm2 inhibition, and the resulting elevation in p53 function, on tumor suppression and aging.
Results and Discussion

Mdm2 deficiency and p53 function
Through the use of wild-type (+), hypomorphic (puro), and null (⌬7-12) mdm2 alleles, we have generated mice with a range of Mdm2 levels (mdm2 rysa et al. 2003) . In all mdm2 puro/⌬7-12 tissues tested, the level of Mdm2 is reduced to ∼30% of the level in wildtype mice, based on RNA and protein analyses ( Fig. 1A ; Mendrysa et al. 2003) . Our initial characterization of mdm2 puro/⌬7-12 mice demonstrated that the ∼70% decrease in Mdm2 results in the stimulation of p53 target gene expression in all tissues examined (Mendrysa et al. 2003) . In addition, the basal apoptotic function of p53 is elevated in a subset of mdm2 puro/⌬7-12 tissues (Mendrysa et al. 2003) . For example, in the small intestines of mdm2 puro/⌬7-12 mice, spontaneous, p53-dependent apoptosis is increased 17-fold over that in wild-type mice ( Fig. 1B ; p = 0.010). In contrast, the amount of p53-dependent apoptosis is not increased in the colons of mdm2 puro/⌬7-12 mice ( Fig. 1B ; p = 0.720).
Mdm2 puro/⌬7-12
thymocytes also have an increase in p53-dependent apoptosis (two-to threefold) which occurs without a proportional increase in p53 protein levels (Mendrysa et al. 2003) . Further characterization of p53 in mdm2 puro/⌬7-12 mice demonstrates that the increased activity of p53 occurs in the absence of enhanced nuclear localization (Fig.  1C ) or an increase in the activating phosphorylation of Ser18 ( Fig. 1D ; Chao et al. 2003) , further substantiating the notion that release of Mdm2 from the transactivation domain of p53 is sufficient to enhance p53 activity (Momand et al. 1992; Thut et al. 1997; Mendrysa et al. 2003) .
Tumor suppression by reduction of Mdm2 levels
Given that the transactivation and apoptotic activities of p53 are increased in mice with subphysiological levels of Mdm2 (mdm2
), we tested whether this increase in p53 function could suppress the formation of solid tumors. We specifically examined the incidence of tu- −/− MEFs, and irradiated wild-type MEFs, respectively; lane 4 is empty; and lanes 5-10 show whole-cell lysates of thymocytes from mice with four different levels of Mdm2. mSin3a is a loading control.
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Cold Spring Harbor Laboratory Press on September 20, 2017 -Published by genesdev.cshlp.org Downloaded from mors of the small intestine by generating Apc min/+ mice that express one of four levels of Mdm2. Apc min/+ mice were chosen because they have one mutant allele of the adenomatous polyposis coli (Apc) tumor suppressor gene and are prone to spontaneous intestinal adenomas that rarely progress to carcinomas (Moser et al. 1990 ). Loss of p53 exacerbates the numbers of these benign tumors in Apc min/+ mice (Halberg et al. 2000) , suggesting that enhanced p53 would suppress tumor formation. As expected, decreased Mdm2 levels led to a reduction of benign tumors in Apc min/+ mice ( Fig. 2A) puro/⌬7-12 mice) had a further reduction in tumor number, to fewer than three tumors per mouse (p < 0.001), demonstrating that the threefold reduction of Mdm2 profoundly suppresses tumor formation.
Does an increase in p53 activity cause aging?
To determine whether constitutively high p53 activity resulting from decreased levels of Mdm2 leads to premature aging, we recorded the lifespans of a cohort of wildtype and mdm2 puro/⌬7-12 mice (Fig. 3) . Between mice of the two genotypes, there was no difference in either the mean or maximal lifespans. The log rank test indicated no difference in the survival time distributions among the two groups of mice (p = 0.61). The mean survival for wild-type mice was 106 wk whereas that for mdm2 puro/ ⌬7-12 mice was 110 wk (106 and 104 wk, respectively, including mice sacrificed prior to morbidity). Seventyone percent of wild-type mice lived to be at least 24 mo of age, as did 73% of mdm2 puro/⌬7-12 mice (58% and 54%, respectively, including mice sacrificed prior to morbidity). At the end of the study, four long-lived mice had to be sacrificed. They were two wild-type mice that were each 130 wk of age and two mdm2 puro/⌬7-12 mice that were 130 and 137 wk of age.
Fifty percent of aged wild-type mice developed spontaneous hepatomas, whereas only 17% of aged mdm2 puro/⌬7-12 mice did so. This finding is of borderline statistical significance due to the small number of tumors in the aged cohort (p = 0.06). In contrast, a highly significant association between decreased Mdm2 and decreased tumorigenesis is evident when comparing the percentage of mice that developed tumors in more than one tissue. Fifty percent of aged wild-type mice had tumors in more than one tissue whereas only 8.3% of aged mdm2 puro/⌬7-12 mice did (p = 0.014). Thus, an approximately threefold decrease in Mdm2 augments the tumor suppressive activity of p53 without causing a reduction in lifespan.
Next we investigated whether a reduction in Mdm2 elicited a number of aging-related phenotypes that have been ascribed to p53, including decreased body weight, reduced dermal thickness, reduced subcutaneous fat, and osteoporosis (Tyner et al. 2002; Maier et al. 2004 ). Since young mdm2 puro/⌬7-12 mice are 15%-20% lighter than their wild-type counterparts (Mendrysa et al. 2003) , we compared the rates of weight loss in aging mice of both genotypes. From 16 to 26 mo of age, male wild-type mice lost 24.1% of their body weight (n = 4), and male mdm2 puro/⌬7-12 mice lost 21.2% of their body weight (n = 4), indicating no change in weight loss due to excess p53 function (p = 0.84). Neither was there a significant difference in skin thickness in aged mice with different levels of Mdm2 (Fig. 4A) values according to either the t-test (p = 0.771) or nonparametric Wilcoxon test (p = 1.00). Finally, the bone thickness of aged mdm2 puro/⌬7-12 mice was not reduced compared with that of aged wild-type mice (Fig. 4B ). Whereas at ages <94 wk the bones of wild-type mice were significantly thicker than those of mdm2 puro/⌬7-12 mice, mdm2 puro/⌬7-12 mice had significantly thicker bones at ages >122 wk. These changes in bone thickness are more consistent with a model in which p53 prevents rather than accelerates aging. No other aging phenotypes appear different in mdm2 puro/⌬7-12 mice, indicating that any effect of the increased p53 function on aging in these mice must be quite subtle.
The lack of premature aging phenotypes in mice with reduced levels of mdm2 indicates that increases in the function of p53 are not sufficient to cause aging. In both of the murine models used to associate p53 with accelerated aging, mutant p53 proteins lacking the N terminus were expressed along with wild-type protein (Tyner et al. 2002; Maier et al. 2004) . N-terminally truncated forms of p53 can alter the preference of full-length p53 for specific promoters (Bourdon et al. 2005) , suggesting that altered p53 function, not increased p53 function, may accelerate aging.
Tumor suppression without adverse effects
Our results clearly demonstrate that p53 activation achieved through Mdm2 inhibition significantly suppresses tumor formation without the negative consequences of accelerated aging. Although aging in mdm2 puro/⌬7-12 mice was unaffected, previous analyses indicated that lymphopenia and intestinal apoptosis were increased (Mendrysa et al. 2003) and are two potentially detrimental side-effects of elevated p53 function. Given that even mdm2 +/puro mice, which express ∼80% of the level of wild-type Mdm2, were significantly protected against tumor formation, we next determined whether all three tumor-suppressive doses of p53 achieved through Mdm2 inhibition cause lymphopenia and enhanced intestinal apoptosis. We enumerated the number of apoptotic cells in the crypts of the small intestines of 5-wk-old mice expressing 100%, 80%, 50%, or 30% of the wild-type level of Mdm2. Consistent with previous results (Mendrysa et al. 2003) , mdm2 puro/⌬7-12 mice had an ∼15-fold (p < 0.001) increase over the wildtype number of apoptotic cells in the crypts of the small intestine. In contrast, mice with 50% of the level of Mdm2 (mdm2 +/⌬7-12 mice) had only a fourfold increase (p = 0.002) and mice with 80% of the wild-type level of Mdm2 had no increase in apoptotic cells (p = 0.07). Thus a tumor-suppressive dose of ∼80% of the wild-type level of Mdm2 is sufficient to maintain intestinal integrity.
We next counted both white blood cells (WBCs) (Fig. 5 ) and lymphocytes (PBLs) from peripheral blood of 5-wkold mice expressing four levels of Mdm2. Whereas mdm2 puro/⌬7-12 mice showed the expected deficiency in WBCs (p = 0.004), neither mdm2 puro/+ nor mdm2
mice were deficient in these cell types (p = 0.352 and p = 0.171, respectively). Likewise, mdm2 puro/⌬7-12 mice showed a profound decrease in PBLs (p = 0.004), but neither mdm2 puro/+ nor mdm2 +/⌬7-12 mice were deficient (p = 1.00 and p = 0.067, respectively). Thus Mdm2 activity can be reduced ∼20%-50% to prevent tumor formation without causing lymphopenia. Because blood sampling is noninvasive, these results suggest that people taking Mdm2 inhibitors could be readily monitored for signs of lymphopenia. If necessary, their doses could be adjusted to prevent any adverse effects. However, as one note of caution for therapeutic applications of Mdm2 inhibitors, it has been observed that Mdm2 puro/+ mice are slightly radiosensitive and mdm2 puro/⌬7-12 mice are very radiosensitive (Mendrysa et al. 2003) . These findings suggest that careful dosing of Mdm2 inhibitors will be required if combined with radiotherapy.
In addition to many possible uses as a therapeutic target, Mdm2 has great promise as a chemopreventive target. The fact that mdm2 puro/⌬7-12 mice live as long as do wild-type mice demonstrates that Mdm2 inhibitors could be titrated such that they could be tolerated for prolonged periods. The profound decrease in adenomas in Apc min/+ ;mdm2 puro/⌬7-12 mice suggests that inhibitors of Mdm2 may be effective in preventing adenomas in families with inherited mutations in the apc gene (familial adenomatous polyposis cohorts) (Strate and Syngal 2005) . In addition, people who are homozygous for SNP309 in the mdm2 promoter (∼11% of the population) puro/⌬7-12 mice. Each of five sex-matched pairs of aged wild-type (squares) and mdm2 puro/⌬7-12 (triangles) mice were assigned a value (j-score) corresponding to the mean thickness of seven or more regions of bone and analyzed as described in the Materials and Methods. The regression model had a multiple R-squared of 0.934 and thus explains 93.4% of the variance in the bone thickness of the mice. The three vertical lines indicate the ages at which the two regression lines intersect (107 wk) and at which there were significant differences in bone thicknesses among the two genotypes (wild-type thicker at ages <94 wk and less thick at ages >122 wk). are likely to benefit from Mdm2 inhibition (Bond et al. 2004) . Careful titration of Mdm2 inhibitors could theoretically restore their p53 function to wild-type levels and delay or prevent tumorigenesis.
Together, these results demonstrate that constitutively increased p53 activity does not cause accelerated aging and confirm Mdm2 as a promising target for chemoprevention and for cancer therapy.
Materials and methods
Mice
Characterization of mdm2
puro/⌬7-12 mice has been described previously (Mendrysa et al. 2003) . All mdm2 puro/⌬7-12 mice were either C57Bl/ 6 × 129EvSv F1 hybrids or on mixed 129/B6 backgrounds. During the survival study, several mice were sacrificed prior to the onset of morbidity. These include three mice of each genotype that were sacrificed at 88-89 wk of age to ensure matched samples of skin and bone; one mouse died during an eye bleed; four mice with skin lesions were sacrificed on the order of the veterinarian; and two mice of each genotype (130-137 wk of age) were sacrificed at the end of the protocol. Necropsies were performed on all mice and histological identification of tumors was performed on all tissues that had not undergone autolysis. For the intestinal tumor analysis, Apc min/+ mice (Moser et al. 1990 ) on a C57Bl/6 background were used to generate Apc +/+ and Apc min/+ C57Bl/6 × 129EvSv F1 hybrids of four mdm2 genotypes. Animal experiments were carried out in AALAC approved facilities under protocols approved by the Animal Care and Use Committees of the University of Wisconsin (most studies) or the Fred Hutchinson Cancer Research Center (Apc min tumor study).
Protein analysis
Immunoprecipitation/Western blot analysis of Mdm2 protein was performed as described previously (Mendrysa et al. 2003) . For analysis of p53 subcellular localization, nuclear and cytoplasmic extracts were made using a previously described procedure with slight modification (Cheshire and Baldwin 1997) . P53 was detected using AB7 (Oncogene Research Products). Purity of nuclear and cytoplasmic fractions was evaluated using mSin3a as a nuclear marker (Santa Cruz, clone 994). Phospho-p53 Ser18 (human Ser15) was analyzed in whole-cell lysates from isolated thymocytes prepared essentially as described in Mendrysa et al. (2003) . Thirty-five micrograms of lysate were loaded in each lane. Blots were first detected with Ser15 (Cell Signaling, catalog no. #9284) then stripped and redetected with pan-p53 antibody CM5 (Novocastra).
Skin thickness
Dorsal skin samples were taken from six age-and sex-matched pairs of wild-type and mdm2 puro/⌬7-12 mice aged from 88 to 129 wk of age. Samples were immersion-fixed in 10% neutral buffered formalin (NBF) and processed for paraffin embedding. Histological examination was done on 5-µm sections stained with hematoxylin and eosin. Dermal thickness and subcutaneous fat were measured using a 20× microscope objective and a 10× ocular eye piece with inserted grid. Multiple measurements were taken to determine a range.
Bone thickness
Bone samples were taken from five age-and sex-matched pairs of wildtype and mdm2 puro/⌬7-12 mice aged from 88 to129 wk of age. Following immersion-fixation in 10% NBF, bone was decalcified for 48 h. Histological examination was done on 5-µm sections stained with hematoxylin and eosin. Cortical bone thickness (bone marrow space to the external bone surface) was measured for the head, neck, mid-shaft and distal-shaft of the femur and tibia; mid-vertebral body of two mid-thoracic vertebrae; and mid-body of three sternebrae (distal or posterior body closest to the xiphoid process, a middle and a more proximal body) using a 20× microscope objective and a 10× ocular eye piece with inserted grid.
TUNEL
To assess apoptosis, 5-µm sections of the small intestines from mice were stained with the ApopTag-terminal deoxynucleotidyl transferase nick end labeling (TUNEL) kit from Chemicon.
Tumorigenesis
Apc min/+ mice of each of four mdm2 genotypes were sacrificed by CO 2 asphyxiation at 5 mo of age. The entire intestinal tract was removed and fixed in 10% NBF followed by storage in 70% ethanol. Tumors along the length of the small intestine were scored blindly under a dissecting microscope.
Peripheral blood analysis
Peripheral blood was collected and analyzed as described in Mendrysa et al. (2003) .
Statistics
Spontaneous tumor incidence across different genotypes was analyzed via the Fisher Exact Test. Tumor data on Apc min mice was analyzed by means of the Welch modified ANOVA procedure and the Games-Howell multiple comparisons procedure. Both of these techniques were used because they permit group comparisons when group variances are significantly different, as they were in this case (Kirk 1982) . Additionally, the nonparametric Kruskal-Wallis test, with follow-up pairwise MannWhitney Wilcoxon tests was employed. These tests make neither distributional nor homoskedasticity (equality of variance) assumptions.
To determine whether the concentration of peripheral blood lymphocytes or white blood cells differed among mice with different amounts of Mdm2, pairwise Mann-Whitney Wilcoxon tests were run, comparing the mean ranks for each of the other three genotypes with the mean rank for wild-type mice.
The analysis of bone thickness data was done by means of the analysis of covariance (ANCOVA) technique with genotype as the grouping variable, age as the covariate, and a composite measure of bone thickness as the dependent variable (see below). Since the ANCOVA, done via a multiple regression approach, indicated that the best fitting regression lines (age regressed on bone thickness) for the two genotypes had significantly different slopes, the modified Johnson-Neyman (Potoff et al. 1964 ) technique was employed. This technique permits the determination of regions along the covariate (age) axis where the two genotypes have significantly different regression lines and also the regions where they do not have significantly different regression lines.
The composite measure of bone thickness was motivated by the fact that each of the mice had potentially thirteen different bone thickness measurements but five (one-half) of the mice had one or more missing measurements. Five had complete data, two had one missing measurement, two had three missing measurements, and one had six missing measurements. Since each measure was of a different bone, a measure had to be developed to summarize the bone thickness for a mouse. For each mouse the z-transform was computed for each measure for which there was data for the mouse. The z-transform is equal to the mouse's score on the measure minus the mean (across mice) on the measure, with this difference divided by the standard deviation (across mice) on this measure. The z-transform has a mean of zero and a standard deviation of one. The z-transforms were in turn rescaled to a "j" transform, having a mean of 100 and a standard deviation of 10. Therefore, for each mouse there are varying numbers of j-transforms depending on the number of bone measurements reported for the mouse. The composite measure that served as a common measure of bone thickness for each mouse was the mean of its available j-transforms. Thus each mouse had a single index, reflecting its relative standing with respect to bone thickness.
